Project Grant K23HL179403
- Federal Grant Award Summary The University of Iowa received a $422,075 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with a completion date of July 31, 2027. The grant funds development of an electromagnetic-actuated dynamic cell culture system designated "MagniWell-12," designed to advance research on airway epithelial cells by simulating physiological stretch-relax...
- Federal Grant Award Summary The University of Iowa received a Project Grant of $248,999 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 4, 2025, through July 31, 2028. The award funds research into mesenchymal cell plasticity and signaling mechanisms in lung regeneration following severe injury. The project investigates how specific mesenchymal cell lineages—particularly PDGFRα-expressing (alpha+)...
- Federal Project Grant Award Summary Purdue University received a $150,011 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with a completion date of July 31, 2029. The project develops an artificial intelligence (AI)-guided intraoral multimodal active sound sensing system integrated into a smart pacifier device for real-time, continuous respiratory monitoring in neonates. The...
- Federal Grant Award Summary The University of Iowa received a $783,781 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 15, 2026, with a completion date of March 31, 2031. This research initiative investigates the role of residential bioaerosol exposure in pulmonary sarcoidosis, a rare systemic inflammatory disease affecting approximately 90% of patients' lungs, with one-third progressing to...
- Federal Project Grant Award Summary Iowa State University of Science and Technology received a $1.18 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through August 31, 2029. The award funds development of a Scientific Machine Learning (SciML)-accelerated cardiovascular digital twin platform designed to personalize long-term heart valve interventions for valvular heart...
- Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The University of Iowa a $1,512,933 Project Grant on August 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) for the "Characterizing a High-Reliability Implementation Program for Sepsis: Sepsis Tools AND Accurate Reporting of Outcome Differences (STANDARD) Study." This research initiative extends through May 31, 2029, and aims to identify organizational features and performance...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $782,289 to the University of Utah under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2025, for a project extending through May 31, 2029. This Project Grant supports research to develop and validate machine learning (ML) models that incorporate donor lung computed tomography (CT) imaging data to predict severe primary graft dysfunction (PGD)—acute lung injury occurring within...
- Federal Grant Award Summary Oregon Health & Science University received a $737,378 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 5, 2026, with completion targeted for March 31, 2031. The award funds a longitudinal follow-up study of preterm infants enrolled in a prior randomized clinical trial evaluating Extended Continuous Positive Airway Pressure (ECPAP) therapy. The research builds on...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Washington a Project Grant of $186,408 (awarded September 1, 2025; completion date August 31, 2030) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop predictive models for identifying patients at high risk for persistent hypoxemic respiratory failure (HRF). The research addresses a critical clinical need by leveraging machine learning and data science to analyze...
- Federal Project Grant Award Summary The University of Illinois received a $109,076 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 30, 2025, with completion anticipated by September 29, 2030. This project develops individualized prediction methods for heart failure (HF) progression using digital twin technology and explainable machine learning. The research addresses a critical gap in...
The University of Iowa received a $188,676 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2026, through April 30, 2031. The award funds development of a clinical decision support (CDS) tool utilizing machine learning (ML) to predict extubation readiness in premature infants requiring mechanical ventilation in neonatal intensive care units (NICUs). The deliverables include an ML-based prediction model incorporating physiologic data from continuous vital signs and ventilator parameters alongside clinical data, validated across two clinically distinct medical centers and compared against published logistic regression algorithms. The grant also supports development of a unified protocol for evaluating neonatal extubation readiness using the Consolidated Framework for Implementation Research, informed by surveys and interviews with clinical stakeholders. The project aims to identify evidence-based informatics implementation strategies to facilitate adoption of the prediction model in a future multicenter clinical trial. By addressing the critical gap in standardized extubation readiness assessment tools, this research seeks to reduce infant morbidity and mortality associated with both prolonged mechanical ventilation and premature extubation failure, particularly bronchopulmonary dysplasia and other chronic lung diseases in at-risk neonatal populations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $188.7k | 6/30/26 |